Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.